Skip to content
Home
Technology
Pipeline
Our Companies
Leadership
Leadership Voices
News & Events
Join Us
Contact
News & Events
Our latest news
[image placeholder – do not delete]
Select Company
All
Altavant
Enzyvant
Myovant
Spirovant
Sumitovant
Urovant
July 14, 2021
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
July 06, 2021
Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
June 01, 2021
Myovant Sciences to Present at Upcoming Investor Conferences
May 26, 2021
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 26, 2021
Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies
May 21, 2021
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 20, 2021
Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study
May 12, 2021
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
May 06, 2021
Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
May 03, 2021
Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
« Previous
1
2
3
4
5
6
…
21
Next »